Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Source: MedTech Dive
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Doctors ‘Cringe’ at Possibility of Documenting...
Pregnant Woman’s Roadside Death Triggers Push To...
Abbott discloses cyberattack on cancer diagnostics...
Employers push health savings plans, nutritional...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.